NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS)

https://www.newamsterdampharma.com

NewAmsterdam (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient LDL-lowering therapy. In multiple Phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. *

	Start	2024-04-01 existent
	Group	NewAmsterdam Pharma (Group)
	Industry	obicetrapib (TA-8995, formerly AMG 899)
	Industry 2	drug development
	Person	Davidson, Michael (NewAmsterdam Pharma 202008 CEO before Corvidia Therapeutics)

	Region	Naarden
	Country	Netherlands
	Street	2-35 Gooimeer
	City	1411 DC Naarden
		Address record changed: 2024-04-07

Basic data	Employees	B: 11 to 50 (2023-12-31)
	Currency	USD
	Annual sales	14,090,000 (revenue, annual, consolidated (2023) 2023-12-31)
	Profit	-176,937,000 (2023-12-31)
	Cash	340,450,000 (2023-12-31)

		* Document for »About Section«: NewAmsterdam Pharma Company N.V.. (4/1/24). "Press Release: NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer". Naarden & Miami, FL.

		Record changed: 2024-07-19